This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rodu, B. Articles by Jansson, C. Search for Related Content PubMed PubMed Citation Social Bookmarking                         What's this?

SMOKELESS TOBACCO AND ORAL CANCER: A REVIEW OF THE RISKS AND DETERMINANTS

¹ Department of Pathology, School of Medicine, LHRB 156, University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA;
² Research and Development Department, Swedish National Food Administration, Uppsala, Sweden

Correspondence: ^* corresponding author, rodu{at}uab.edu

CONTROVERSY Most health professionals recognize that smokeless tobacco (SLT) use is associated with oral cancer. However, many have an exaggerated perception of the magnitude of the risk, and there is little understanding or discussion of historical and contemporary scientific data relevant to the association. This review by Rodu and Jansson establishes that SLT use carries only modest risk for oral cancer, and it further describes the key agents in SLT that play important roles in raising—or even lowering—this risk. In other words, it challenges conventional perceptions about SLT use and provides interesting and surprising information about SLT products. — Olav Alvares, Editor

 

Smokeless tobacco has been associated with oral cancer for many decades. The purpose of this article is to review research relevant to this association, including epidemiologic studies, studies of putative carcinogens such as tobacco-specific nitrosamines (TSNAs) and other contaminants, and possible cancer inhibitors. Epidemiologic studies addressing this issue primarily consist of case-control studies. They show that the use of chewing tobacco and moist snuff is associated with very low risks for cancers of the oral cavity and related structures (relative risks [RR] from 0.6 to 1.7). The use of dry snuff is associated with higher RRs, ranging from 4 to 13, while the RRs from smokeless tobacco, unspecified as to type, are intermediate (RR = 1.5 to 2.8). With regard to TSNAs, historical levels in American moist snuff products were higher than those in their Swedish counterparts, but levels in contemporary products are uniformly low. TSNA levels in chewing tobacco have always been low, but levels in dry snuff have been higher, including some very high levels in current products. In general, smokeless tobacco users are not exposed to significant levels of cadmium, lead, benzo(a)pyrene, polonium-210, and formaldehyde, when compared with concentrations of these compounds in foods. Finally, low oral cancer risk from smokeless tobacco use may be influenced by the presence of cancer inhibitors, mainly anti-oxidants, in smokeless tobacco products.

Key Words: Smokeless tobacco • oral cancer • case-control studies • tobacco-specific nitrosamines • anti-oxidants

Critical Reviews in Oral Biology & Medicine, Vol. 15, No. 5, 252-263 (2004)
DOI: 10.1177/154411130401500502


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Chen, C. J. Marsit, B. C. Christensen, E.A. Houseman, M. D. McClean, J. F. Smith, J. T. Bryan, M. R. Posner, H. H. Nelson, and K. T. Kelsey Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer Carcinogenesis, June 1, 2009; 30(6): 977 - 981. [Abstract] [Full Text] [PDF]

				B. Stenstrom, C.-M. Zhao, A. B. Rogers, H.-O. Nilsson, E. Sturegard, S. Lundgren, J. G. Fox, T. C. Wang, T. M. Wadstrom, and D. Chen Swedish moist snuff accelerates gastric cancer development in Helicobacter pylori-infected wild-type and gastrin transgenic mice Carcinogenesis, September 1, 2007; 28(9): 2041 - 2046. [Abstract] [Full Text] [PDF]

				P. N Lee Circulatory disease and smokeless tobacco in Western populations: a review of the evidence Int. J. Epidemiol., August 1, 2007; 36(4): 789 - 804. [Abstract] [Full Text] [PDF]

				P. K. Avti, S. Kumar, C. M. Pathak, K. Vaiphei, and K. L. Khanduja Smokeless Tobacco Impairs the Antioxidant Defense in Liver, Lung, and Kidney of Rats Toxicol. Sci., February 1, 2006; 89(2): 547 - 553. [Abstract] [Full Text] [PDF]

				H Furberg, C M Bulik, C Lerman, P Lichtenstein, N L Pedersen, and P F Sullivan Is Swedish snus associated with smoking initiation or smoking cessation? Tob. Control, December 1, 2005; 14(6): 422 - 424. [Abstract] [Full Text] [PDF]

				X. Wen and T. Walle Preferential induction of CYP1B1 by benzo[a]pyrene in human oral epithelial cells: impact on DNA adduct formation and prevention by polyphenols Carcinogenesis, October 1, 2005; 26(10): 1774 - 1781. [Abstract] [Full Text] [PDF]